Get started

Biotech

Breakthrough Discovery: AccuTOX Effectively Kills Cancer Cells by @newsfile on 2 Aug 2022, 03:15 Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly due to losses in the ability of a given cell to activate its own cell death via a specific set of proteins known to sense unusual activities. Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this. Defence previously reported (see press release of June 22, 2021) the discovery of an AccumTM variant, AccuTOXTM, capable of controlling cancer growth when injected directly in tumors. The use of AccuTOXTM in combination with multiple immune-checkpoints results in a survival rate between 60% and 100%, based on the pre-clinical tumor models studies in mice. The mode of action of AccuTOXTM approached is a non-biased transcriptomic application and revealed that the compound impairs several crucial pathways including DNA replication, cell division, nuclear integrity, and multiple modifications affecting DNA activity. The accumulation of exhaustive cell repair mechanisms triggered by AccuTOXTM combined to the build-up of misfolded proteins and generation of free radicals induce irreversible DNA damages leading to a general collapse in several cellular pathways resulting in effective cancer cell death. "Defence's breakthrough discovery with its AccuTOXTM formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with AccumTM. Discovering that AccuTOXTM can behave as a chemotherapeutic agent targeting the DNA of cancer cells and an immune-checkpoint inhibitor booster is a new discovery that is highly valuable to Defence's pipeline and future potential developments. The AccuTOXTM presents a novel discovery as a platform for targeting multiple cancers. This novel discovery creates significant values and applications to our Antibody Drug Conjugate ("ADC") pipeline. Results are convincing that AccuTOXTM is the perfect potent small molecule to use in the development of our own ADC," says Mr. Plouffe, the CEO of Defence Therapeutics. Defence is currently conducting GLP studies on AccuTOXTM prior to initiate a Phase I trial in North America.
CSE:DTCLong
by wealth_bakery
BioNTech showing a solid entryBNTX is finally concluding a year long descending triangle pattern. I see a low risk entry at $150 and will be buying. Stop loss set at $138.49, risking about 8.5%. If we see a large move upward, I could see the stock retesting both its 200 day moving average (likely at $183) and its next major resistance after that at $295. A potential of nearly 100% profit (not to say its a sure bet or smart to dump huge amounts into the trade without the stop loss...). Fundamentally, the company has a P/E of 3, no debt, and a huge free cash flow to fund its mrna platforms for a lot of other diseases partnering with some of the largest pharma companies in the world. Yet another variant of covid, upward pressure from the 50and100 day MAs, large portions of the world unvaccinated, and president biden contracting the virus could be potential catalysts for a move. If you're looking for a bio tech exposure this is a stock that seems to be set up well. Good luck to all.
NASDAQ:BNTXLong
by Avatar_Trading
1
Green in the sea of red: Biotech (2)Summary This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound. Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction. S&P500 Nasdaq100 To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic. We recommend more conservative traders to execute the idea with AMEX:XLV (link here: ), while more aggressive traders can go with AMEX:XBI (this post) which is relatively volatile. Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital Technical The 250 days moving average of AMEX:XBI is pointing downward, and it is currently trading below the 250 days moving average, which confirms the down trend is still effective for AMEX:XBI . Benchmarking with NASDAQ:QQQ (Nasdaq100 index ETF), although both are in similar down trend, AMEX:XBI 20 days moving average has already crossed the 50 days moving average while that of NASDAQ:QQQ still running below, which shows stronger confirmation of the rebound for AMEX:XBI than NASDAQ:QQQ . Here are some important level one should pay attentions to: Downside support 72.55: Jun-30 retest low after breaking 50 days moving average 61.78: May-12 52 weeks low Upside resistance 84.63: Jul-8 high after breaking 50 days moving average 97.19: Apr-5 high before creating new low on May-12 118.23: 2021 May-10 consolidation bottom, which was broken, retested and continued to the downside during 2021 Nov to Dec
AMEX:XBILong
by geoffreyip523
Green in the sea of red: Healthcare (1)Summary This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound. Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction. S&P500 Nasdaq100 To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic. We recommend more conservative traders to execute the idea with AMEX:XLV (this post), while more aggressive traders can go with AMEX:XBI (link here: ) which is relatively volatile. Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital Technical AMEX:XLV is still outperforming major indexes. Instead of downtrend, AMEX:XLV is still in a consolidation period. AMEX:XLV has been trading in extending box range since Oct-2021, with 1 extension to the upside in Dec-2021, and 1 extension to the downside this year on Jun-13. The more than 8 months of consolidation period has flattened the 250 days moving average, yet not bending it downward (yet?). 20 days and 50 days moving averages have been crossing each other multiple times during the consolidation period, making them less indicative from a technical perspective. Currently AMEX:XLV is trading below 250 days moving average, tested but failed to penetrate the moving average on Jul-8, if it still cannot get above the 250 days moving average in the coming months, the downside pressure will materialize into an actual down trend. In summary, these are the important levels one should pay attention to: Downside support 118.75: Jun-13 new box bottom 109.74: Post covid peak before rallying to the upside Upside resistance 132.04: Jul-8 attempt of breaking 250 days moving average 143.42: Apr-8 new box top
AMEX:XLVLong
by geoffreyip523
$XLV:$KRE: Deflation winners and losersWe're seeing value health care ($XLV) show a lot of relative strength against other sectors as the dollar has been pushing. ($KRE) is often tied to growth when compared to it's bigger brother ($XLF) and eventhough financials do tend to benefit from rising rates, this has been much more of a hard landing and the financial rotation many expect may not come to pass, instead look for $XLV to continue soaking up 2022 when compared to other sectors.
AMEX:XLVLong
by Fox_Technicals
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
NASDAQ:MREOLong
by BADQOMOCAWGOWLD
$RYTM Next Target PTs 5.50-6.50 and higherRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
NASDAQ:RYTMLong
by BADQOMOCAWGOWLD
$BVNRY PTs 300-400 and higher Bavarian Nordic is the only company with an FDA approved Monkey Pox Vaccine Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
OTC:BVNRYLong
by BADQOMOCAWGOWLD
1
XBI outlook on future medicine We see it in our favorite sci fi movies: the cure for cancer, biotech armor, mind altering substances to enhance intelligence, so on so forth. Assuming this index is the representation of biotech importance, I'd like to hear ideas for how biotech would crash. Everything we've seen from the movies can be reasons for an increase in price.. but what would cause the destruction of biotech funding? Is it even possible? If we want to achieve space exploration.. how could biotech ever fail? Thanks.
AMEX:XBILong
by W40kProfit
SESEN Bio - A possible Jump & Run?The market is bleeding, but may be you know this quote: "Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria" - Sir John Templeton So the actual question is, where are we right now? I guess "Euphoria" is actually over and we are on our steady way down to realistic valuations. Let's talk facts: As of March 31, 2022, $SESN had $169.8 million in cash and cash equivalents, no outstanding debt and fewer than 0.2 million outstanding warrants. What is in their pipeline? They are currently developing Vicineum, a locally administered fusion protein, for the treatment of non-muscle invasive bladder cancer (NMIBC). What happened to the stock price? A few months ago the FDA had determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. The stock price dropped dramatically and now trades around 0.50$. What is BLA? BLA, Biologics License Application, is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). What opportunities lie ahead? Let me tell you, trading bio-tech stocks requires strong guts and control of emotions - I speak from experience. Currently the company is considering two things: 1. Reverse Split, so that they will remain listed on the NASDAQ 2. Selling the company to maximize shareholder value The development of Vicineum will continue and they seek another meeting with the FDA soon to discuss further steps for BLA approval with an additional Phase 3 testing. The 2nd option sounds like a good strategy, the balance sheet looks healthy, the product itself seems promising, so that I had to invest a little bit (10% of my account size). As soon as the company had communicated that they consider selling the company, the stock jumped a nice 30% - luckily I had bought it a few days earlier. Now we can see a little bit of pullback, which seems more like accumulation, rather than distribution. The volume on the declining candles is lower and the strong buy volume after the news actually speaks a different story. You can check my chart for levels (white are monthly and purple are the weekly levels of support and resistance). Let's see what will happen, but the most important thing is patience, as well as proper risk management. Stay healthy!
SLong
by RedFoxTrading
2
CRXT Clarus Therapeutics Bullish ReversalCRXT Clarus Therapeutics had 3 green days after its sell-off to all time low. This should signal a reversal pattern. Clarus Therapeutics has the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions called JATENZO. The fist target is the $1.1 private placement offering price and then the $2.10 resistance. Few months ago they had another private placement at $4.96 per unit, so we can take that into consideration as well. Needham & Company LLC has a Price Target of $8 for CRXT (that is the ultimate goal). I think it can easily double from here. Looking forward to read your opinion about it.
CLong
by TopgOptions